Tonix Pharmaceuticals Holding financials
$9.65−2.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.5M | $6.9M | $5.4M | $3.3M | $2.0M | $2.4M | $2.6M | $2.8M | $2.2M | $2.5M | $3.8M | $4.0M |
| Gross profit | $12.8M | $5.3M | $4.3M | $1.9M | -$1.3M | $1.5M | $1.4M | $1.3M | -$1.2M | $822.0K | $1.4M | $1.6M |
| Gross margin | 94.8% | 77.1% | 80.4% | 58.4% | −63.8% | 61.2% | 54.2% | 44.9% | −52.5% | 33.1% | 37.4% | 40.5% |
| Operating income | -$42.5M | -$41.5M | -$48.3M | -$33.1M | -$28.3M | -$16.1M | -$22.5M | -$15.6M | -$77.3M | -$21.4M | -$27.3M | -$28.1M |
| Net income | -$40.6M | -$40.2M | -$46.9M | -$32.0M | -$28.3M | -$16.8M | -$22.1M | -$14.2M | -$78.8M | -$14.9M | -$27.3M | -$28.0M |
| Net margin | −299.4% | −584.4% | −870.3% | −972.9% | −1415.0% | −692.8% | −856.2% | −503.6% | −3567.8% | −601.9% | −723.0% | −701.3% |
| Diluted EPS | $-2.44 | $-2.93 | $-3.95 | $-3.59 | $-3.86 | $-2.84 | $-9.83 | $-22.68 | $-1920.85 | $-535.72 | $-1545.02 | $-3863.00 |
| EBITDA | -$41.9M | -$41.0M | -$47.8M | -$32.6M | -$27.8M | -$15.6M | -$22.0M | -$15.0M | -$17.2M | -$20.1M | -$26.1M | -$26.9M |
| Operating cash flow | -$42.2M | -$42.3M | -$39.6M | -$28.8M | -$14.8M | -$16.6M | -$14.6M | -$18.8M | -$9.9M | -$17.6M | -$22.3M | -$23.4M |
| Free cash flow | -$42.8M | -$44.0M | -$41.5M | -$29.7M | -$15.4M | -$16.6M | -$14.6M | -$18.8M | -$9.9M | -$17.7M | -$22.8M | -$25.2M |
| Diluted shares | 16.6M | 13.7M | 11.9M | 8.9M | 7.3M | 5.9M | 2.2M | 0.6M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $176.2M | $185.5M | $207.6M | $190.1M | $125.3M | $131.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $254.1M | $257.9M | $277.2M | $252.4M | $187.4M | $192.9M |
| Total liabilities | $31.8M | $30.8M | $32.0M | $21.3M | $19.4M | $12.5M |
| Shareholders' equity | $222.3M | $227.1M | $245.2M | $231.1M | $168.0M | $180.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology